Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Leerink Lowers PT after Ironwood Pharmaceuticals (IRWD) 1Q Results
May 6, 2015 11:00 AM EDTLeerink Partners reiterates a Market Perform rating on Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and lowers its price target to $16 (from $17) after weak 1Q sales. The Linzess profit share fell short of street expectations due to challenging sales, and seasonality, the analyst notes
Leerink analyst... More
Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
May 5, 2015 5:07 PM EDTIronwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.24), may note compare the analyst estimate of ($0.23). Revenue for the quarter came in at $28.9 million versus the consensus estimate of $32.3 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
... More